Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Long-Term Investments (2017 - 2018)

Amicus Therapeutics' Long-Term Investments history spans 4 years, with the latest figure at $13.8 million for Q2 2018.

  • For the quarter ending Q2 2018, Long-Term Investments changed N/A year-over-year to $13.8 million, compared with a TTM value of $13.8 million through Jun 2018, changed N/A, and an annual FY2014 reading of $17.5 million, changed N/A over the prior year.
  • Long-Term Investments for Q2 2018 was $13.8 million at Amicus Therapeutics, down from $42.7 million in the prior quarter.
  • The five-year high for Long-Term Investments was $42.7 million in Q1 2018, with the low at $482000.0 in Q2 2015.
  • Average Long-Term Investments over 4 years is $13.3 million, with a median of $13.8 million recorded in 2018.